A Meta-analysis on Relationship between Epidermal Growth Factor 61A/G Polymorphism and Risk of Hepatocellular Carcinoma
-
摘要: 目的 探讨内皮生长因子(EGF）基因多态性与肝细胞性肝癌(HCC)发病风险的关系。 方法计算机系统检索PubMed、EMABSE 和中国知网等数据库，收集关于EGF 61A/G基因多态性与HCC易感性的病例对照研究，并从纳入文献中提取相关数据进行Meta分析。以病例组和对照组EGF 61A/G基因型分布的比值比(OR）为效应指标，对纳入文献进行异质性检验，应用Stata 10.1软件对各研究原始数据进行合并分析，计算合并OR值及其95%可信区间(CI）。结果共有6篇文献符合纳入标准，累计病例1 304例，对照2 613例。 G/G基因型与G/A+A/A基因型比较的OR值为1.34 (95% CI 1.16~1.54，P<0.001；I2 =36%)。而A/A基因型与G/G+G/A基因型比较的OR值为0.66 (95% CI 0.53~0.83，P<0.001 ；I2 =0%)。结论EGF 61G/G基因型为罹患HCC的易感基因型，而EGF 61A/A基因型则为HCC的保护基因型。Abstract: Objective To explore the relationship between polymorphism of epidermal growth factor (EGF) 61A/G and the risk of hepatocellular carcinoma(HCC). MethodsElectronic searches of PubMed，EMBASE and CNKI were systematically conducted to select studies.Case-control studies containing available genotype frequencies of EGF 61A/G were chose.Odds ratio (OR) with 95% confidence interval (CI) was used to assess the strength of this association. Results Six case-control studies including 1 304 cases and 2 613 controls were performed.Meta-analysis showed significant effect of EGF 61A/G on HCC risk and protection (G/G vs.G/A+A/A：OR=1.34，95%CI=1.16~1.54；A/A vs.G/G+G/A：OR=0.66，95% CI=0.53~0.83). Conclusion The EGF 61G allele is a risk factor of HCC;however，the EGF 61A allele is a protective factor of HCC.
-
Key words:
- EGF /
- Polymorphism /
- Hepatocellular carcinoma /
- Meta-analysis
-
-
[1] Urtasun R，Latasa MU，Demartis MI，et al.Connective tissue growth factor autocriny in humanhepatocellular carcinoma：Oncogenic role and regulation by epidermal growth factor receptor/yes-associated protein-mediated activation[J].Hepatology，2011，54(6):2149-2158. [2] Kmüves LG，Feren A，Jones AL，et al.Expression of epidermal growth factor and its receptor incirrhotic liver disease[J].J Histochem Cytochem，2000，48(6):821-830. [3] Lanuti M，Liu G，Goodwin JM，et al.A functional epidermal growth factor (EGF) polymorphism，EGFserum levels，and esophageal adenocarcinoma risk and outcome[J].Clin Cancer Res，2008，14(10):3216-3222. [4] Xu W，Li Y，Wang X，et al.Association between EGF promoter polymorphisms and cancer risk：ameta-analysis[J].Med Oncol，2010，27(4):1389-1397. [5] Qi P，Chen YM，Gao CF，et al.Relationship between polymorphism of epidermal growth factor 5'UTRVariant G61A gene and hepatocellular carcinoma in patients with chronic hepatitis B virus infectionin China[J].Zhongguo Sheng Wu Zhi Pin Xue Za Zhi，2008，21(12):1051-1053.[戚鹏，陈岳明，高春芳，等.EGF +61基因多态性与乙型肝炎细胞癌的相关性[J].中国生物制品学杂志，2008，21(12):1051-1053.] [6] Abu Dayyeh BK，Yang M，Fuchs BC，et al.A functional polymorphism in the epidermal growth factorgene is associated with risk for hepatocellular carcinoma[J].Gastroenterology，2011，141(1):141-149. [7] Tanabe KK，Lemoine A，Finkelstein DM，et al.Epidermal growth factor gene functionalpolymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis[J].JAMA，2008，299(1):53-60. [8] Li Y，Xie Q，Lu F，et al.Association between epidermal growth factor 61A/G polymorphism andhepatocellular carcinoma susceptibility in Chinese patients[J].Liver Int，2010，30(1):112-118. [9] Qi P，Wang H，Chen YM，et al.No association of EGF 5'UTR variant A61G and hepatocellularcarcinoma in Chinese patients with chronic hepatitis B virus infection[J].Pathology，2009，41(6):555-560. [10] Chen K，Wei Y，Yang H，et al.Epidermal growth factor +61 G/A polymorphism and the risk ofhepatocellular carcinoma in a Chinese population[J].Genet Test Mol Biomarkers，2011，15(4):251-255. [11] Wang HX，Xie WM，Zhou GQ.Epidermal growth factor gene polymorphism associated withsusceptibility to hepatocellular carcinoma[D].Guangxi Medical University，2009.[王洪学，谢伟敏，周钢桥.表皮生长因子基因多态性与肝癌的遗传关联研究[D].广西：广西医科大学，2009.] [12] Casula M，Alaibac M，Pizzichetta MA，et al.Role of the EGF +61A>G polymorphism in melanomapathogenesis：an experience on a large series of Italian cases and controls[J].BMC Dermatol，2009，9:7. [13] Llovet JM，Bruix J.Molecular targeted therapies in hepatocellular carcinoma[J].Hepatology，2008，48(4):1312-1327. [14] Ji H，Li D，Chen L，et al.The impact of human EGFR kinase domain mutations onlungtumorigenesis and in vivo sensitivity to EGFR-targeted therapies[J].Cancer Cell，2006，9(6):485-495. [15] Ciardiello F，Tortora G.EGFR antagonists in cancer treatment[J].N Engl J Med，2008，358(11):1160-1174.
计量
- 文章访问数: 2392
- HTML全文浏览量: 17
- PDF下载量: 639
下载:
